|
US3887699A
(en)
|
1969-03-24 |
1975-06-03 |
Seymour Yolles |
Biodegradable polymeric article for dispensing drugs
|
|
US3854480A
(en)
|
1969-04-01 |
1974-12-17 |
Alza Corp |
Drug-delivery system
|
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
DE3169595D1
(en)
|
1980-11-10 |
1985-05-02 |
Gersonde Klaus |
Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
|
|
US4675189A
(en)
|
1980-11-18 |
1987-06-23 |
Syntex (U.S.A.) Inc. |
Microencapsulation of water soluble active polypeptides
|
|
PH19942A
(en)
|
1980-11-18 |
1986-08-14 |
Sintex Inc |
Microencapsulation of water soluble polypeptides
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
DE3218121A1
(de)
|
1982-05-14 |
1983-11-17 |
Leskovar, Peter, Dr.-Ing., 8000 München |
Arzneimittel zur tumorbehandlung
|
|
EP0102324A3
(de)
|
1982-07-29 |
1984-11-07 |
Ciba-Geigy Ag |
Lipide und Tenside in wässriger Phase
|
|
US4452775A
(en)
|
1982-12-03 |
1984-06-05 |
Syntex (U.S.A.) Inc. |
Cholesterol matrix delivery system for sustained release of macromolecules
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
ATE159858T1
(de)
|
1983-09-26 |
1997-11-15 |
Ehrenfeld Udo |
Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr
|
|
US4615885A
(en)
|
1983-11-01 |
1986-10-07 |
Terumo Kabushiki Kaisha |
Pharmaceutical composition containing urokinase
|
|
DE3413608A1
(de)
|
1984-04-11 |
1985-10-24 |
Hoechst Ag, 6230 Frankfurt |
Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5133974A
(en)
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
ES2113940T3
(es)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
IT1247472B
(it)
|
1991-05-31 |
1994-12-17 |
Fidia Spa |
Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
|
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US5407686A
(en)
|
1991-11-27 |
1995-04-18 |
Sidmak Laboratories, Inc. |
Sustained release composition for oral administration of active ingredient
|
|
US5470582A
(en)
|
1992-02-07 |
1995-11-28 |
Syntex (U.S.A.) Inc. |
Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
DK0674506T3
(da)
|
1992-12-02 |
2001-01-08 |
Alkermes Inc |
Væksthormonholdige mikrosfærer med styret frigivelse
|
|
US6372716B1
(en)
|
1994-04-26 |
2002-04-16 |
Genetics Institute, Inc. |
Formulations for factor IX
|
|
DE69519382T3
(de)
|
1994-09-09 |
2008-09-18 |
Takeda Pharmaceutical Co. Ltd. |
Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
|
|
ATE212545T1
(de)
|
1995-03-28 |
2002-02-15 |
Fidia Advanced Biopolymers Srl |
Nanosphären mit einem biokompatiblen polysaccharid
|
|
WO1996040072A2
(en)
|
1995-06-07 |
1996-12-19 |
Alkermes Controlled Therapeutics, Inc. |
Composition for sustained release of human growth hormone
|
|
ZA965368B
(en)
|
1995-07-14 |
1997-01-14 |
Novo Nordisk As |
A pharmaceutical formulation
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
US5736152A
(en)
|
1995-10-27 |
1998-04-07 |
Atrix Laboratories, Inc. |
Non-polymeric sustained release delivery system
|
|
ES2375931T3
(es)
|
1997-12-05 |
2012-03-07 |
The Scripps Research Institute |
Humanización de anticuerpo murino.
|
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6566329B1
(en)
|
1999-06-28 |
2003-05-20 |
Novo Nordisk A/S |
Freeze-dried preparation of human growth hormone
|
|
AU2001238677A1
(en)
*
|
2000-02-28 |
2001-09-12 |
Idec Pharmaceuticals Corporation |
Method for preparing anti-mif antibodies
|
|
US7217517B2
(en)
*
|
2001-07-23 |
2007-05-15 |
Senesco Technologies, Inc. |
Nucleic acids, polypeptides, and methods for modulating apoptosis
|
|
EP1544291A4
(en)
|
2002-07-19 |
2006-08-02 |
Towa Kagaku Co Ltd |
A NEW METHOD FOR THE PRODUCTION OF ANTIBODY CYME, NEW ANTIBODY CYM AND USE THEREOF
|
|
CA2490007C
(en)
|
2002-07-19 |
2011-05-24 |
Omeros Corporation |
Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
|
|
EP1576952A1
(en)
|
2004-03-18 |
2005-09-21 |
OctoPlus Technologies B.V. |
Hydrogel microspheres with improved release profile
|
|
CA2561686C
(en)
|
2004-03-31 |
2014-12-02 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
PT1737891E
(pt)
|
2004-04-13 |
2013-04-16 |
Hoffmann La Roche |
Anticorpos anti p-selectina
|
|
US20060030003A1
(en)
*
|
2004-05-12 |
2006-02-09 |
Simon Michael R |
Composition and method for introduction of RNA interference sequences into targeted cells and tissues
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
EP1951890A4
(en)
|
2005-11-16 |
2009-06-24 |
Ambrx Inc |
PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
|
|
KR101423898B1
(ko)
|
2005-12-14 |
2014-07-28 |
암브룩스, 인코포레이티드 |
비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
|
|
EP1978989A4
(en)
|
2005-12-30 |
2009-03-18 |
Ambrx Inc |
AMINO ACIDS AND NON-NATURAL POLYPEPTIDES, COMPOSITIONS CONTAINING THEM, METHODS INVOLVING THEM AND USES THEREOF
|
|
CN101384711A
(zh)
|
2006-01-19 |
2009-03-11 |
Ambrx公司 |
具有经调节的免疫原性的非天然氨基酸多肽
|
|
WO2008077079A1
(en)
|
2006-12-18 |
2008-06-26 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
AU2007341997A1
(en)
|
2006-12-28 |
2008-07-10 |
Ambrx, Inc. |
Phenazine and quinoxaline substituted amino acids and polypeptides
|
|
WO2009045536A2
(en)
*
|
2007-10-05 |
2009-04-09 |
The University Of North Carolina At Chapel Hill |
Receptor targeted oligonucleotides
|
|
JO3076B1
(ar)
*
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
NO2337846T3
(enExample)
|
2008-09-26 |
2018-06-16 |
|
|
|
WO2010073694A1
(ja)
|
2008-12-25 |
2010-07-01 |
国立大学法人東京大学 |
抗tm4sf20抗体を用いた癌の診断と治療
|
|
US20110117660A1
(en)
*
|
2009-11-16 |
2011-05-19 |
Brooks Douglas G |
Physical characterization of oligonucleotide conjugates
|
|
EP2714685B1
(en)
|
2011-05-27 |
2016-10-19 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
|
|
CN103717595A
(zh)
|
2011-05-27 |
2014-04-09 |
Ambrx公司 |
含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
|
|
RU2655439C2
(ru)
*
|
2013-05-31 |
2018-05-28 |
Займворкс Инк. |
Гетеромультимеры с уменьшенной или подавленной эффекторной функцией
|
|
BR112015030514A2
(pt)
*
|
2013-06-04 |
2017-08-29 |
Cytomx Therapeutics Inc |
Composições e métodos para conjugação de anticorpos ativáveis
|
|
JP2016531920A
(ja)
*
|
2013-09-05 |
2016-10-13 |
アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． |
Ｃｄ７０結合ペプチドおよびそれに関連する方法、プロセスおよび用途
|
|
CA2926087C
(en)
*
|
2013-10-10 |
2023-03-14 |
Beth Israel Deaconess Medical Center, Inc. |
Tm4sf1 binding proteins and methods of using same
|
|
TWI703160B
(zh)
*
|
2015-11-30 |
2020-09-01 |
美商輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
|
EP3315139B1
(en)
*
|
2016-10-28 |
2021-12-15 |
Technische Universität Dresden |
A delivery system for targeted delivery of a therapeutically active payload
|
|
JP7241080B2
(ja)
*
|
2017-08-28 |
2023-03-16 |
アンジーエックス・インコーポレーテッド |
抗ｔｍ４ｓｆ１抗体およびそれを使用する方法
|
|
US12458705B2
(en)
|
2018-06-12 |
2025-11-04 |
Angiex, Inc. |
Antibody-oligonucleotide conjugates
|